NIH VideoCast - Demystifying Medicine - Taxol: Discovery, Mechanism and Cancer Treatment

Skip Navigation

Demystifying Medicine - Taxol: Discovery, Mechanism and Cancer Treatment

Loading... Loading video...

429 Views

Air date:	Tuesday, January 28, 2020, 4:00:00 PM Time displayed is Eastern Time, Washington DC Local
Views:	Total views: 429 (99 Live, 330 On-demand)
Category:	Demystifying Medicine
Runtime:	01:23:16
Closed captioning:	Check box to display CC outside of the video Note: You can drag the captioning window around and resize it
Description:	Demystifying Medicine Lecture Series Taxol is a commercial name for paclitaxel, a natural-based cancer drug originally derived from the bark of the Pacific yew tree. The drug has proven to be effective in treating numerous cancer types, including ovarian, breast, cervical, and lung cancers. Taxol is among the most affordable and best-selling chemotherapy drugs, with annual sales over $1 billion. Horwitz, the Rose C. Falkenstein Chair in Cancer Research at Einstein, was among the first to study the anticancer properties of Taxol in the late 1970s. She discovered that Taxol was able to bind to a cell's microtubule assembly and slow cell division and growth, blocking the segregation of chromosomes. More recently she has investigated Taxol drug resistance. On the clinical side, Lee, an NIH–Lasker Clinical Research Scholar, is a principal investigator on several ongoing phase 1 and 2 studies at the NIH Clinical Center involving olaparib (PARP inhibitor) in combination with paclitaxel and other biologic agents. The Demystifying Medicine Lecture Series is designed to help bridge the gap between advances in biology and their applications to major human diseases. The lectures include presentations of patients, pathology, diagnosis, and therapy in the context of major diseases and current research. All clinicians, trainees including fellows, medical students, Ph.D. students, and other healthcare and research professionals are welcome to attend. For more information go to https://demystifyingmedicine.od.nih.gov

NLM Title:	Demystifying medicine. Taxol : discovery, mechanism and cancer treatment / Susan Band Horwitz and Jung-Min Lee.
Author:	Horwitz, Susan Band. Lee, Jung-Min.
Publisher:
Abstract:	(CIT): Demystifying Medicine Lecture Series. Taxol is a commercial name for paclitaxel, a natural-based cancer drug originally derived from the bark of the Pacific yew tree. The drug has proven to be effective in treating numerous cancer types, including ovarian, breast, cervical, and lung cancers. Taxol is among the most affordable and best-selling chemotherapy drugs, with annual sales over $1 billion. Horwitz, the Rose C. Falkenstein Chair in Cancer Research at Einstein, was among the first to study the anticancer properties of Taxol in the late 1970s. She discovered that Taxol was able to bind to a cell's microtubule assembly and slow cell division and growth, blocking the segregation of chromosomes. More recently she has investigated Taxol drug resistance. On the clinical side, Lee, an NIH-Lasker Clinical Research Scholar, is a principal investigator on several ongoing phase 1 and 2 studies at the NIH Clinical Center involving olaparib (PARP inhibitor) in combination with paclitaxel and other biologic agents. The Demystifying Medicine Lecture Series is designed to help bridge the gap between advances in biology and their applications to major human diseases. The lectures include presentations of patients, pathology, diagnosis, and therapy in the context of major diseases and current research.
Subjects:	Ovarian Neoplasms--drug therapy Paclitaxel--pharmacology Paclitaxel--therapeutic use Phthalazines--therapeutic use Piperazines--therapeutic use
Publication Types:	Lecture Webcast

NLM Classification:	QV 269
NLM ID:	101762248
CIT Live ID:	35576
Permanent link:	https://videocast.nih.gov/watch=35576

Related Videos...